Marengo Therapeutics

Marengo Therapeutics is a clinical-stage Cambridge, Massachusetts company developing TCR-targeting antibodies that selectively modulate T-cell subsets. Its STAR platform (precision T-cell agonist) bispecifics include invikafusp alfa, in clinical development as monotherapy in immune checkpoint blockade-resistant, tumour mutational burden-high tumours (START-001) and in an antibody-drug conjugate combination in breast cancer (START-002), plus partnered STAR programmes. The TriSTAR platform (precision T-cell engager) includes TriSTAR0701 targeting Nectin-4 for bladder and other cancers and several partnered candidates, and the MSTAR platform (precision T-cell depleter) is aimed at autoimmune disease. Marengo's news page lists Apple Tree Partners as lead investor. Financing amounts and series were not stated on fetched pages.